Novel Research Findings
Am J Nephrol
DOI: 10.1159/000522226
Received: November 23, 2021
Accepted: January 17, 2022
Published online: March 24, 2022
Genetic Etiologies for Chronic Kidney
Disease Revealed through
Next-Generation Renal Gene Panel
Anthony J. Bleyer a Maggie Westemeyer b Jing Xie b Michelle S. Bloom b
Katya Brossart b Jason J. Eckel c Frederick Jones c Miklos Z. Molnar d
Wayne Kotzker e Prince Anand f Stanislav Kmoch a, g Yuan Xue h
Samuel Strom h Sumit Punj b Zachary P. Demko b Hossein Tabriziani b
Paul R. Billings b Trudy McKanna b
aSection
on Nephrology, Wake Forest School of Medicine, Winston-Salem, NC, USA; bNatera, Inc., San Carlos, CA,
USA; cNorth Carolina Nephrology Associates, Cary, NC, USA; dDivision of Nephrology & Hypertension, Department
of Medicine, University of Utah, Salt Lake City, UT, USA; eFlorida Kidney Physicians, Boca Raton, FL, USA;
fMUSC Lancaster, Lancaster, SC, USA; gResearch Unit for Rare Diseases, Department of Pediatrics and Adolescent
Medicine, First Faculty of Medicine, Charles University, Prague, Czechia; hFulgent Genetics, Temple City, CA, USA
Keywords
Genetic testing · Chronic kidney disease · Next-generation
sequencing · Nephrology
Abstract
Introduction: Chronic kidney disease (CKD) is a major public
health issue in the USA. Identification of monogenic causes
of CKD, which are present in ∼10% of adult cases, can impact
prognosis and patient management. Broad gene panels can
provide unbiased testing approaches, which are advantageous in phenotypically heterogeneous diseases. However,
the use and yield of broad genetic panels by nephrologists
in clinical practice is not yet well characterized. Methods: Renal genetic testing, ordered exclusively for clinical purposes,
predominantly by general and transplant nephrologists
within the USA, was performed on 1,007 consecutive unique
patient samples. Testing was performed using a commercially available next-generation sequencing-based 382 gene
kidney disease panel. Pathogenic (P) and likely pathogenic
Karger@karger.com
www.karger.com/ajn
© 2022 The Author(s).
Published by S. Karger AG, Basel
This is an Open Access article licensed under the Creative Commons
Attribution-NonCommercial-4.0 International License (CC BY-NC)
(http://www.karger.com/Services/OpenAccessLicense), applicable to
the online version of the article only. Usage and distribution for commercial purposes requires written permission.
(LP) variants were reported. Positive findings included a
monoallelic P/LP variant in an autosomal dominant or Xlinked gene and biallelic P/LP variants in autosomal recessive genes. Results: Positive genetic findings were identified
in 21.1% (212/1,007) of cases. A total of 220 positive results
were identified across 48 genes. Positive results occurred
most frequently in the PKD1 (34.1%), COL4A5 (10.9%), PKD2
(10.0%), COL4A4 (6.4%), COL4A3 (5.9%), and TTR (4.1%) genes.
Variants identified in the remaining 42 genes comprised
28.6% of the total positive findings, including single positive
results in 26 genes. Positive results in >1 gene were identified in 7.5% (16/212) of cases. Conclusions: Use of broad
panel genetic testing by clinical nephrologists had a high
success rate, similar to results obtained by academic centers
specializing in genetics.
© 2022 The Author(s).
Published by S. Karger AG, Basel
Anthony J. Bleyer and Maggie Westemeyer contributed equally to
this work.
Correspondence to:
Anthony J. Bleyer, ableyer @ wakehealth.edu
Introduction
Chronic kidney disease (CKD) affects 37 million adults
in the USA [1]. Recent studies suggest that disease-causing genetic variants are identifiable in ∼10% of adults and
~20% of children with CKD [2, 3], most of whom are unaware of the genetic etiology for their kidney dysfunction.
Identification of monogenic causes of CKD can inform
prognosis, personalize treatments, inform counseling
and testing of at-risk relatives, influence reproductive decision-making, and enable referrals for evaluation of extrarenal manifestations. For the ∼800,000 individuals in
the USA with end-stage kidney disease (ESKD), genetic
diagnosis may inform the selection of potential-related
kidney donors, assess the risk of disease recurrence, and
guide clinical management following transplant.
Broad gene panels offer several advantages over mutational analysis of individual genes or targeted panels. The
phenotypic variability of rare and multisystem disorders,
including the unpredictable interaction of causative variants, complicates the selection of appropriate targets [3,
4]. Screening for single-gene disorders in a stepwise manner can preclude identification of the causative variants
and can be expensive and time consuming. Broad gene
panels provide an economical, comprehensive analysis
that can reduce barriers to testing by streamlining testing
procedures, reimbursement, report structure, and genetic counseling capabilities.
To date, most studies utilizing genetic testing for kidney disease focus on selected cohorts with a high suspicion for monogenic disorders in an academic setting or
have tested an unselected population of individuals with
CKD as part of a systematic approach to determine the
prevalence of genetic disorders causing kidney disease [3,
5–10]. Additionally, most of these studies perform genetic testing using whole-exome sequencing (WES) or with
a panel of genes selected based on clinical presentation.
One recent study that tested 127 patients with kidney diseases with a broad genetic panel, comprised of 177 genes
identified positive findings in 43% of patients [11]. In addition to these seminal studies, characterizing the results
of genetic testing performed exclusively for clinical purposes and ordered by nephrologists in clinical practice
will provide an understanding of the real-world value of
these tests. Understanding the testing patterns and the
yield and scope of test findings will provide better insight
into the clinical utility of genetic testing and how to improve its application in nephrology.
Recently, Natera, Inc. developed a next-generation sequencing (NGS)-based broad panel test for the identifica2
Am J Nephrol
DOI: 10.1159/000522226
tion of monogenic causes of CKD. This panel encompasses genes associated with disorders spanning multiple
types of kidney diseases, including cystic, tubulointerstitial, glomerular, tubular, and structural disorders. Additionally, this panel covers a broad range of diseases from
those which primarily affect the kidney to multisystem
diseases with known renal components. The panel, which
included 382 genes, was designed to capture both wellestablished and rare genetic kidney diseases, as well as
multi-organ syndromes that may be missed through targeted tests. The panel is available to clinicians in the USA,
and the ordering of this test is solely at the discretion of
the clinical nephrologist and the patient. Here, we present
the findings from the first 1,007 tests performed with this
broad panel for kidney diseases.
Materials and Methods
Study Subjects
This study was a retrospective analysis of 1,007 consecutive
tests performed on patients with a 382 renal gene NGS panel (the
RenasightTM test, Natera, San Carlos, CA, USA). These tests were
ordered by transplant and general nephrologists at 204 clinics
across the USA between May and September 2020. Demographic
information of the patients tested, including age, ethnicity, sex,
transplant status, and testing indications (ICD-10 codes) specifying CKD stage and a limited set of CKD diagnoses was provided
on the requisition form by the patient or physician (Table 1, online
suppl. Table S1; for all online suppl. material, see www.karger.
com/doi/10.1159/000522226). Patients were determined to be affected either by the ICD-10 code or the clinical information provided by the clinician on the requisition form. Thus, there is a discrepancy between the number of cases analyzed based on ICD-10
codes and with affected status (Table 1, online suppl. Table S1). All
patients or legal guardians (in the cases of minors) provided informed consent for the performance of genetic testing and the data
were de-identified prior to analysis. The study was performed in
adherence with the Declaration of Helsinki.
Panel Design
The broad renal genetic panel included 382 genes associated
with cystic and tubulointerstitial disorders, glomerular disorders,
complement-related kidney disorders, congenital anomalies of the
kidney and urinary tract (CAKUT) and structural disorders, tubulopathy and tubular disorders, diabetic nephropathies, hypertension-related disorders, nephrolithiasis, and electrolyte abnormalities (online suppl. Table S2) [3].
Renasight NGS Panel Sequencing and Data Analysis
Genomic DNA isolated from the accessioned samples (blood
or buccal saliva) was prepared into libraries using a customized
hybrid capture enrichment protocol targeting key coding exons
and splicing junctions based on IDT xGen Lockdown probe chemistry (Integrated DNA Technologies, Inc., Coralville, IA, USA).
Paired-end sequencing was then performed on DNA libraries on
Bleyer et al.
Table 1. Demographics of patients
Age range
All patients
Positive cases
N = 1,007
(%)
250
(%)
≤18
19–29
30–39
40–49
50–59
60–69
70–79
>80
21
144
234
170
171
164
84
19
(2.1)
(14.3)
(23.2)
(16.9)
(17.0)
(16.3)
(8.3)
(1.9)
1
41
68
60
41
26
11
2
(0.4)
(16.4)
(27.2)
(24.0)
(16.4)
(10.4)
(4.4)
(0.8)
Ethnicity
All patients
Positive cases
N = 737
(%)
N = 204
(%)
African American
Ashkenazi Jewish
Asian
Caucasian
East Asian
Hispanic
Mediterranean
Pacific Islander
Southeast Asian
Sephardic Jewish
South Asian
Mixed/Other
171
9
1
381
6
120
4
2
14
2
9
18
(23.3)
(1.2)
(0.1)
(51.7)
(0.8)
(16.3)
(0.5)
(0.3)
(1.9)
(0.3)
(1.2)
(2.4)
59
0
0
101
3
27
3
0
2
1
4
4
(28.9)
(0.0)
(0.0)
(49.5)
(1.5)
(13.2)
(1.5)
(0.0)
(1.0)
(0.5)
(2.0)
(2.0)
Affected status
All patients
Affected
Unaffected
Positive cases
N = 973
(%)
N = 220
(%)
924
49
(95.0)
(5.0)
210
10
(95.5)
(4.5)
the Illumina platform 2,500 HiSeq or NovaSeq 6,000, using 300bp
reads. The average coverage across the panel was >150× with
99.6% of the targeted regions covered at ≥20×. Copy number was
calculated from NGS coverage data using a customized algorithm
[12], which involved comparing normalized exonic coverage to
controls.
AD and AR diseases, clinical relevance was interpreted based on
variant type, frequency, molecular mechanism of disease, and
previously reported clinical cases in literature. Heterozygous P/
LP variants within the COL4A3 and COL4A4 were considered
positive, as were heterozygous P/LP variants in COL4A5 in female patients [14].
Variant Interpretation
All variants detected in the reportable region (i.e., coding exons and ±20bp flanking introns) were assessed based on the
American College of Medical Genetics and Genomics guideline
for sequence variant interpretation [13]. Variants were classified
into five-tier categories: pathogenic (P), likely pathogenic (LP),
variants of uncertain significance (VUS), likely benign and benign. P and LP variants were reported and VUS findings were
reported if requested by the provider but were not considered
positive results. A monoallelic P/LP variant in an autosomal
dominant (AD) or X-linked gene, and biallelic P/LP variants in
an autosomal recessive (AR) gene were considered as positive
findings. One P/LP variant in an AR gene imparted carrier status. For P/LP variants identified in genes associated with both
Confirmatory Analysis
Confirmatory testing was performed for all P/LP cases, except
for copy number events spanning ≥12 exons not overlapping regions of genomic complexity. When needed, confirmatory testing
of the NGS-detected variants was performed on the original DNA
sample. Sequence variants detected by NGS were confirmed by
Sanger sequencing. Sequence variants detected in the regions with
pseudogenes or homologous sequences were confirmed by longrange PCR followed by Sanger sequencing. Deletions or duplications were confirmed as indicated by quality score by an orthogonal method (qPCR or MLPA). Deletions or duplications in the
PKD1 and PKD2 genes were confirmed by SALSA® MLPA®
Probemix (P351-C1 for PKD1, P352-D1 for PKD1-PKD2).
Genetic Testing for Chronic Kidney
Disease
Am J Nephrol
DOI: 10.1159/000522226
3
Table 2. Positive genes
Gene
Associated conditions
Positive Inheritance Kidney
disease
results, pattern
category*
n
ABCC8
ADCY10
ALPL
APOL1
ATP6V0A4
ATP6V1B1
AVPR2
BBS1
CASR
Familial hyperinsulinemia hypoglycemia, diabetes mellitus
Absorptive hypercalciuria
Hypophosphatasia
Susceptibility to end-stage renal disease; focal segmental glomerulosclerosis 4
Renal tubular acidosis, distal
Renal tubular acidosis with deafness
Diabetes insipidus, nephrogenic
Bardet-Biedl syndrome
Hypocalcemia; familial hypocalciuric hypercalcemia with transient neonatal
hyperparathyroidism
Focal segmental glomerulosclerosis
Hemolytic uremic syndrome, atypical; complement factor I deficiency
Stickler syndrome
HANAC
Alport syndrome, COL4A3-related
Alport syndrome, COL4A4-related
Alport syndrome, X-linked
Megaloblastic anemia 1, Finnish type
Familial hypercalcemia
Polycystic kidney and/or polycystic liver disease 3
Beta-hemoglobinopathies (HbSC disease)
Diabetes mellitus; maturity-onset diabetes of the young, type 3
Renal cysts and diabetes syndrome
Fanconi renotubular syndrome 4, with maturity-onset diabetes of the young, type 1
Focal segmental glomerulosclerosis 5; Charcot-Marie-tooth disease E
Congenital hyperinsulinism; permanent neonatal diabetes mellitus
Obesity risk
Familial Mediterranean fever
Nephrotic syndrome, type 2
Pseudohypoaldosteronism type I, autosomal dominant hypertension, early-onset
Joubert syndrome, type 10; orofaciodigital syndrome I; Golabi-Behmel syndrome, type 2
Isolated renal hypoplasia; papillorenal syndrome; focal segmental glomerulosclerosis 7
CAKUTHED
Polycystic kidney disease 1
Polycystic kidney disease 1/tuberous sclerosis contiguous gene deletion
Polycystic kidney disease 2
Autosomal recessive polycystic kidney disease
Polycystic liver disease 1
Noonan syndrome 1
Gitelman syndrome
Fanconi renotubular syndrome 2; hypercalcemia, infantile, 2; nephrolithiasis/
osteoporosis, hypophosphatemic, 1
Cystinuria
Renal tubular acidosis, distal
Cystinuria
Pulmonary hypertension, primary 2
Tuberous sclerosis 2
Amyloidosis, hereditary, transthyretin-related
Medullary cystic kidney disease 2; hyperuricemic nephropathy; glomerulocystic kidney
disease
Von Hippel-Lindau syndrome
Pseudohypoaldosteronism, type 2B
Denys-Drash syndrome; Frasier syndrome; nephrotic syndrome, type 4
1
1
1
57
1
1
1
2
1
AD/AR
AD
AD/AR
Complex
AR
AR
XL
AR
AD/AR
T, G, D, H
T
T
G
T
T
T
CS, CTI
T
2
3
2
2
13
14
24
1
2
1
1
1
1
2
3
2
1
1
2
1
1
1
1
75
1
22
2
1
1
3
1
AD/AR
AD/AR
AD
AD
AD/AR
AD/AR
XL
AR
AR
AD
AD/AR
AD/AR
AD
AD
AD
AD/AR
AD/AR
AR
AR
AD
XL
AD
AD
AD
AD
AD
AR
AD
AD
AR
AD/AR
G
CR
CS?
CTI
G
G
G
G
T
CTI
G, T
CTI
CTI, CS, D
G, D
G
G, D
D, H
G
G
T, H
CTI
CS, G
CS
CTI
CTI
CTI
CTI
CTI
CS
T
T
4
1
1
1
1
9
2
AD/AR
AD/AR
AD/AR
AD
AD
AD
AD
T
T
T
T, H
CTI
G
CTI
1
2
1
AD
AD
AD
CTI
T
CS, G
CD2AP
CFI
COL11A1
COL4A1
COL4A3
COL4A4
COL4A5
CUBN
CYP24A1
GANAB
HBB
HNF1A
HNF1B
HNF4A
INF2
KCNJ11
MC4R
MEFV
NPHS2
NR3C2
OFD1
PAX2
PBX1
PKD1
PKD1/TSC2 gene deletion
PKD2
PKHD1
PRKCSH
PTPN11
SLC12A3
SLC34A1
SLC3A1
SLC4A1
SLC7A9
SMAD9
TSC2
TTR
UMOD
VHL
WNK4
WT1
HANAC, hereditary angiopathy with nephropathy, aneurysms, and muscle cramps; CAKUTHED, congenital anomalies of the kidney and urinary tract
syndrome with or without hearing loss, abnormal ears, or developmental delay. * Kidney disease categories: CTI, cystic and tubulointerstitial disorders; G,
glomerular disorders; CR, complement-related kidney disorders; CS, congenital anomalies of the kidney and urinary tract (CAKUT) and structural disorders; T,
tubulopathy and tubular disorders (tubular ion transport, nephrolithiasis, cystinuria, nephrogenic diabetes); D, diabetes-related; H, hypertension-related.
4
Am J Nephrol
DOI: 10.1159/000522226
Bleyer et al.
Results
Positive findings
Patient Characteristics
Renal genetic testing was performed on samples from
1,007 individuals with a median age of 46 years (range
5–91), of which, 52.7% (531/1,007) were female. Information about a patient’s kidney disease status was available
for 96.5% (973/1,007) of cases, of which 95.0% (924/973)
were affected (Table 1). Testing indications, as designated
by ICD-10 codes, were provided for 933 patients, of
which, CKD (stages 1–5 or unspecified), or ESKD were
submitted as the indication for 76.4% (713/933) of the
tests ordered (online suppl. Table S1).
Ethnicity was reported for 73.2% (737/1,007) of cases,
of which 51.7% (381/737) were Caucasian, 23.2%
(171/737) were African American (AA), and 16.3%
(120/737) were Hispanic. Among those with positive
findings from genetic testing (n = 260; including APOL1),
the median age was 44 years (range: 18–89), and the proportion of each ethnic group was similar to that of the full
cohort (Table 1).
PKD1
COL4A5
PKD2
COL4A4
COL4A3
TTR
SLC3A1
CFI
INF2
SLC12A3
BBS1
CD2AP
COL11A1
COL4A1
CYP24A1
HNF4A
KCNJ11
NPHS2
PKHD1
TSC2
UMOD
WNK4
ABCC8
ADCY10
Fig. 1. Positive findings from testing with renal gene panel. Frequency of positive P/LP findings in each of 48 different genes (excluding APOL1) was determined out of 220 total positive results in
212 individuals. Frequency of positive findings in PKD1 and TSC2
include a PKD1/TSC2 contiguous deletion identified in 1 case.
Genetic Findings
Of 1,007 individuals tested, 220 positive P/LP variants
were identified across 48 genes (excluding APOL1) in 212
cases (Table 2, Fig. 1). Among the positive P/LP variants
identified, 10 copy number variations were identified in
nine genes, including a large deletion of PKD1 and TSC2
(online suppl. Table S3). Positive P/LP variants were
identified most frequently in the PKD1 (34.1%), COL4A5
(10.9%), PKD2 (10.0%), COL4A4 (6.4%), COL4A3 (5.9%),
and TTR (4.1%) genes. Disease-causing P/LP variants
identified in the remaining 42 genes comprised 28.6% of
the total positive findings. A single positive P/LP result
was identified in 26 genes, representing 11.8% of the 220
total positive results (shown in Fig. 1).
Among the 220 positive P/LP findings, the most frequent genetic diagnoses were AD polycystic kidney disease (ADPKD; 45.0%; n = 99), Alport syndrome (23.2%,
n = 51), amyloidosis (4.1%; n = 9), focal segmental glomerulosclerosis (FSGS, 2.7%; n = 6), and cystinuria (2.3%;
n = 5). Together, these five conditions comprised 77.2%
of the total positive P/LP findings (shown in Fig. 2).
Biallelic G1 and G2 alleles in the APOL1 gene confer an
increased risk for the development of FSGS. Among the
cohort, positivity for these APOL1 high-risk genotypes
(G1/G1, G1/G2, G2/G2) were identified in 57 individuals
(Table 2). The G1 and G2 alleles are present at a high frequency in individuals of African descent. Among the
high-risk genotype-positive cases in our cohort, 77.2%
Genetic Testing for Chronic Kidney
Disease
Am J Nephrol
DOI: 10.1159/000522226
ALPL
ATP6V0A4
ATP6V1B1
AVPR2
CASR
CUBN
GANAB
HBB
HNF1A
HNF1B
MC4R
MEFV
NR3C2
OFD1
PAX2
PBX1
PRKCSH
PTPN11
SLC34A1
SLC4A1
SLC7A9
SMAD9
VHL
WT1
0
10
20
30
40
Frequency of positive findings, %
5
Other
(23.2%)
Fig. 2. Top positive disorders identified by
renal genetic testing. Disorders associated
with positive P/LP variants identified in 48
genes were categorized to determine the
most prevalent disorders among the cohort. ADPKD is associated with variants in
the PKD1, PKD2, or GANAB genes; Alport
syndrome is associated with variants in the
COL4A3, COL4A4, or COL4A5 genes, Amyloidosis is associated with variants in the
TTR gene; FSGS is associated with variants
in the INF2, CD2AP, or PAX2 genes; and
Cystinuria is associated with variants in the
SLC3A1 gene.
FSGS (2.7%)
Amyloidosis (4.1%)
(44/57) of cases were AA, 7.0% (4/57) were Hispanic, 1.8%
(1/57) were Caucasian, and ethnicity was not provided for
14.0% (8/57) of cases. Together, positive findings in disease-causing P/LP variants and APOL1 high-risk genotypes were identified in 25.8% (260/1,007) of individuals.
Positive findings in more than one gene (including both
P/LP variants and APOL1 high-risk genotypes) were identified in 16 cases, 9 of whom were positive for an APOL1
high-risk genotype (online suppl. Table S6).
We assigned the 220 positive P/LP findings and their
associated conditions to one or multiple broad kidney
disease categories that we defined based on the framework developed by the ClinGen Kidney Disease Working
Group [15]. Positive P/LP findings were most prevalent
in genes associated with cystic and tubulointerstitial disorders (51.4%, 113/220), glomerular diseases (35.0%,
77/220), and tubulopathies (10.9%, 24/200) (Table 2).
Additionally, 6.4% of the total positive findings were in
genes and associated conditions that were assigned multiple kidney disease categories, highlighting the variable
presentations of many kidney disorders (Table 2; online
suppl. Fig. S1).
Identification of carriers for variants in AR genes has
implications for reproductive and family planning. Carriers of one P/LP variant in one or more AR kidney disease genes or of one G1 or G2 allele in APOL1 were identified in 45.3% (457/1,007) of cases; 23.0% (105/457) of
6
Am J Nephrol
DOI: 10.1159/000522226
ADPKD
(45.0%)
Cystinuria (2.3%)
Alport syndrome
(23.2%)
these cases also had positive findings in other genes. In
total, 604 carrier variants were identified in 131 genes
(online suppl. Table S1). VUS were reported in 100%
(340/340) of cases where requested, with a mean number
of 7 VUS identified (range 1–18).
Renal Genetic Test Findings among African
Americans (AA)
In the USA, the incidence of developing ESKD is approximately 4-fold higher among AAs as compared to
Caucasians [16]. This disparity is largely attributed to the
high rate of positivity for APOL1 high-risk genotypes. In
our cohort, either positive P/LP variants or APOL1 highrisk genotypes were identified in 34.5% (59/171) of AA
patients, across 12 genes. Positivity for APOL1 high-risk
genotypes was identified in 74.6% (44/59) of the positive
AA cases (Table 2). Among other findings in AA individuals, 5 cases were positive for variants in PKD1 (6.7%
of all PKD1 positive cases), 4 in TTR (44.4% of all TTR
cases), and 3 in COL4A4 (21.4% of all COL4A4 cases).
Unique positive findings were identified in the CASR,
COL4A1, CUBN, HBB, PKD2, PTPN11, and SLC3A1
genes (online suppl. Table S5).
Reports have indicated that individuals with sickle cell
trait (SCT) in the HBB gene may be at increased risk for
the development of CKD [17]. Carriers of the HBB gene
were identified in 15.2% (26/171) of AA patients, repreBleyer et al.
senting 66.7% (26/39) of all HBB carriers in our cohort.
Five HBB carriers (4 AA; 1 unknown ethnicity) were also
positive for APOL1 high-risk genotypes, representing
7.0% of all APOL1-positive cases.
Discussion/Conclusion
Positive Findings among CKD and ESKD Patients,
and Kidney Transplant Recipients
Testing indications, based on ICD-10 codes were provided for 243 cases with positive findings (either P/LP
variants or APOL1 high-risk genotypes). Kidney transplant status information was provided by physicians for
202 of these positive cases. We investigated the positive
findings among a sub-cohort of these cases for which severity of kidney disease progression was indicated (CKD
stages 1–5 or unspecified, ESKD, or kidney transplant recipient [KTR]).
CKD or ESKD was indicated for 78.2% (190/243) of
cases with positive results, of which 35.2% (67/190) had
positive findings in the PKD1 or PKD2 genes, 23.2%
(44/190) were positive for an APOL1 high-risk genotype
and 15.3% (29/190) had positive findings in COL4A3,
COL4A4, or COL4A5 (online suppl. Table S1, S7).
KTR comprised 8.1% (82/1,007) of patients in the cohort. Positive P/LP variants or APOL1 high-risk genotypes were identified in 29.3% (24/82) of KTR in 13 genes,
including 2 cases with positive findings in multiple genes.
Findings included positivity for an APOL1 high-risk genotype (4.2%; 10/24) and variants in the COL4A3, COL4A4, or COL4A5 genes (16.7%; 4/24), which are associated with Alport syndrome (online suppl. Table S8).
Among our cohort, 24 individuals were tested for potential organ donation. Positive findings (including P/LP
variants and APOL1 high-risk genotypes) were identified
in 29.2% (7/24) of these cases, spanning multiple genes,
including 4 patients with high-risk genotypes in APOL1
(online suppl. Table S7).
Here, we report the genetic findings observed during
clinical use of a broad panel for monogenic kidney disorders by general and transplant nephrologists. This realworld application of this broad panel genetic test resulted
in a positive genetic finding rate of 21.1%. In comparison,
previously reported rates of positive findings have ranged
from 9.3% in a cohort of unselected CKD/ESKD patients
[3] to 51% in cohorts that were selected based upon family history, early onset of disease, or high suspicion of genetic kidney disease [6, 7, 10]. In our study, test ordering
was determined solely at the discretion of the physician
and patient, and criteria likely varied between physicians.
As a result, the cohort tested likely included a combination of CKD/ESKD patients with low and high suspicions
of genetic kidney disease, as well as asymptomatic individuals that may have been tested as a part of family testing or donor evaluation. Thus, the rate of positive findings in our cohort reflects selective screening and identification of at-risk patients by nephrologists.
The genetic variants identified in this cohort encompassed a large range of genes and associated kidney diseases. Most of the positive findings were identified in six key
genes; however, the remaining 28.6% of findings involved
42 genes in which variants were only observed in 1 to 4 patients. The high rate of overall findings in this long tail of
genes highlights the value of a broad panel. The genes in
which positive findings were identified as associated with
conditions that span multiple disease types, including cystic, glomerular, tubulointerstitial, and electrolyte disorders.
Additionally, many of these conditions can have phenotypes that could be classified into multiple kidney disease
categories. The heterogeneity among the conditions for
which positive findings were identified among this cohort
suggests that genetic testing with a broad panel could assist
in accurate diagnosis when clinical tools are insufficient.
The largest disease groups for which positive diseasecausing genetic findings were identified were ADPKD
and Alport syndrome (collagen 4A disorders), reflecting
findings in other cohorts of CKD patients referred for genetic testing [3, 10]. Testing for monogenic causes of ADKPD can enable diagnosis when ultrasound criteria alone
cannot exclude individuals without a family history, in
individuals with atypical presentation, or in younger patients with fewer or smaller cysts [18]. As variants in additional genes, such as GANAB and DNAJB11 have been
implicated in atypical presentation of ADPKD or can
have phenotypic overlap with non-ADPKD disorders, diagnoses based on ultrasound alone have become more
Genetic Testing for Chronic Kidney
Disease
Am J Nephrol
DOI: 10.1159/000522226
Unaffected Cases with Positive Findings
Among cases for which either positive P/LP variants
or APOL1 high-risk genotypes were identified, 3.8%
(10/260) were clinically unaffected at the time of testing,
and 1.5% (4/260) had an unknown disease status. Of the
unaffected patients, five were prior or potential kidney
donors, four of whom had APOL1 high-risk genotypes,
and two were positive for variants in either PKD1 or
PKD2 and reported family histories of PKD. One patient
with an LP CD2AP gene variant, which is associated with
FSGS, for which no family history information was available, had preconception genetic testing performed to
evaluate reproductive risk.
7
complicated [18]. Knowledge of the underlying genetic
component can influence prognosis and treatment of
ADPKD [19]. For instance, patients with mutations in
PKD1 are likely to have a more rapid decline in eGFR and
benefit from emerging treatments such as tolvaptan [20].
Furthermore, presentation or treatment of the disease
can be complicated by the presence of P/LP variants in
additional genes, which was observed in 5.1% (5/99) of
PKD1, PKD2, or GANAB-positive cases in our cohort.
Positive findings in variants associated with Alport syndrome were also highly prevalent in our cohort. Collagen
disorders such as Alport syndrome may be difficult to diagnose clinically, as cardinal features such as hearing loss and
hematuria present variably. Among CKD patients referred
for genetic testing, 62% of those with COL4A mutations do
not have a clinical diagnosis of Alport syndrome [3]. Additionally, Alport syndrome can often manifest as FSGS, for
which genetic testing can result in reclassification of the
clinical diagnosis [21]. As a result of variability in the clinical presentations of Alport syndrome, recent guidance recommended a classification system for Alport syndrome and
other collagen 4 disorders that include the incorporation of
genetic confirmation [22].
Testing has the potential to influence management for
a multitude of less common genetic kidney diseases that
were identified among our cohort. Variants in INF2,
CD2AP, PAX2, and WT1 can be associated with FSGS and
nephrotic syndrome. As genetic FSGS and nephrotic syndrome are often steroid-resistant [23], testing can result in
avoidance of unnecessary use of glucocorticoids, and its
associated toxicity. Variants in HNF1B can be associated
with hypomagnesemia, asymptomatic liver function test
abnormalities, gout, and progressive kidney disease,
which can be treated if detected. Identification of variants
in CUBN, which causes Imerslund-Grasbeck syndrome,
can inform disease prognosis, as these individuals often
have normal renal function and do not need treatment,
despite the presence of proteinuria [24]. Furthermore, as
kidney biopsy is expensive and has serious risks, identification of variants in some genes, including UMOD and
APOL1 have the potential to obviate or supplement a kidney biopsy which may not provide a definitive diagnosis.
AA individuals comprised 23.3% of our cohort, of which,
the most common genetic findings were APOL1 high-risk
genotypes. The G1 and G2 alleles are present in 11%–13%
of people of African ancestry [25, 26], who have a 3.5-fold
higher incidence rate of ESKD compared to Caucasians
[27]. It is generally thought that a second genetic or environmental factor is needed for the development of disease
in individuals with APOL1 high-risk genotypes. In our
8
Am J Nephrol
DOI: 10.1159/000522226
study, P/LP variants in a second gene were identified in
5.8% (9/57) of APOL1-positive cases. Additionally, 44.4%
(4/9) of the positive variants in TTR were in AA patients,
consistent with previous reports for increased risk of TTR
mutations among this population [28, 29]. Evidence also
supports an association between SCT, which is prevalent
among AA individuals, and CKD and decline in eGFR [17,
30]. In our cohort, 15.2% of AA patients were carriers of
HBB, of which 92.3% were affected, much higher than the
8%–9% of all AA with SCT [31]. AA individuals are underscreened for genetic kidney diseases compared to other races [32] but disproportionately comprise the CKD population. The high rates of non-APOL1 findings among the AA
in our cohort (30.5%; 18/59) highlight the importance of
screening AA with a broad gene panel to identify coexisting
causes of inherited kidney disease.
Limitations of this study include a lack of detailed information regarding clinical diagnoses, the purpose of
testing, or clinical follow-up. Testing indications based
on ICD-10 may not be reflective of an accurate clinical
diagnosis, as these codes are required for billing, and physicians are under no obligation to be specific with their
coding. Due to the lack of additional medical history, we
are unable to determine if patients considered “unaffected” are healthy or have other underlying medical conditions that may not have been documented. This limits the
evaluation of the utility of genetic diagnoses in this cohort. Second, this test was initially available only to adult
patients, resulting in an underreporting of pediatric patients. Third, although this gene panel encompasses a
broad range of kidney-related genes and phenotypes, test
results are limited to the scope of the panel and may miss
the identification of certain P/LP variants. Future clinical
studies that include larger cohorts, follow-up information, and healthy controls will be able to further evaluate
the utility of genetic testing with a broad kidney gene panel on the management of patients with CKD.
Our study likely under-represents the true prevalence of
genetic disorders in this population due to VUS and to unknown genetic causes of some disorders. Additionally, certain disease-causing variants, such as those in the MUC1
gene, which account for 1% of ESKD cases [33], cannot be
identified by multigene panels or WES. As variants identified through this genetic test are classified based on American College of Medical Genetics and Genomics criteria,
many VUS are present. For instance, missense variants are
the most common changes identified in the COL4A genes
and as many of these variants are novel, they can be difficult
to classify [14]. Thus, there may be many disease-causing
variants that do not currently have enough evidence to
Bleyer et al.
reach the level of P or LP. As information about genetic
variants increases through additional functional studies,
some VUS will likely be reclassified as disease-causing in
the future. In addition, as more monogenic causes of kidney
disease are identified in the future, expansion of genetic
panels can enable higher positivity rates among patients.
Thus, as with other studies in this area, the rate of positive
findings in this study is likely an underestimate of the true
prevalence of monogenic kidney disorders in this cohort.
Targeted phenotype-driven gene panels and WES
both afford the ability to identify genetic disorders of the
kidney but have drawbacks. Many commercial gene panels are restricted to groups of genes known to be causative
of certain types of kidney disease (i.e., cystic or glomerulopathy). Thus, a negative result may lead to non-discovery of a genetic cause or could lead to subsequent testing
with different disease panels. The comprehensive nature
of WES enables the identification of variants in genes associated with both common and rare kidney disorders, as
well as exploration of diseases for which the renal implications are not well defined. However, WES is costly and
has longer turnaround time. A broad gene panel, such as
the RenasightTM test, combines the benefits of both approaches and avoids the drawbacks.
The use of a broad panel for genetic diagnosis for kidney
diseases has multiple advantages for clinicians, minimizing
the need to identify the correct genetic panel or prioritize
panels for individuals with an overlap of symptoms. Use of
a single test for a wide range of patients allows physicians to
become familiar with a single process for ordering, insurance ascertainment, cost, and results reporting, which have
previously been identified as obstacles for use of genetic
testing among nephrologists [4, 34]. In addition, unexpected findings for rare diseases that were not under consideration will improve diagnostic accuracy.
A recent study using a 177 gene panel spanning ciliopathies/tubulointerstitial diseases, CAKUT, tubular
transport disorders, and glomerulopathies to test a small
cohort of individuals had a diagnostic yield of 43% [11].
This high yield is likely a result of clinicians selecting patients with a high suspicion of genetic kidney disease as
well as the small cohort size. Yields are likely to be lower
when genetic testing is used as part of routine clinical care
of CKD patients.
In summary, genetic results from individuals tested with
the Renasight test, a broad gene panel for evaluation for CKD,
nephrolithiasis, and electrolyte abnormalities, revealed a
high rate of positive findings representing a variety of both
common, and rare genetic diagnoses. Our study revealed cases in which positive findings were identified in more than one
gene. These findings indicate that a broad kidney disease
gene panel is highly effective in identifying monogenic variants underlying inherited kidney diseases and has utility for
genetic diagnoses in the nephrology setting.
Genetic Testing for Chronic Kidney
Disease
Am J Nephrol
DOI: 10.1159/000522226
Statement of Ethics
No ethics approval was required for this study. All patients provided informed consent for genetic testing and the data were deidentified for analysis. The study was performed in adherence with
the Declaration of Helsinki.
Conflict of Interest Statement
A.J.B. received speaker fees from Natera and has served on advisory boards for Horizon Therapeutics. J.J.E. received speaker fees
from Natera, Otsuka, and Astra Zeneca. M.Z.M. received grant/
research support from Viracor and CareDx and served as an advisor for Merck, CareDx, and AbbVie. W.K. is an employee and the
owner of Florida Kidney Physicians; has ownership in/is a consultant for DaVita; received speaker fees and honoraria from Natera,
Otsuka, Opko, and Astra-Zeneca; received research support from
GSK, Tricida, Bayer, Sanifit, DiaMedica, Retrophin, and Astra-Zeneca; and is a member of the advisory boards for Retrophin and
Astra-Zeneca. P.M. received support from Natera, Immunocor,
CareDX, and Veloxis and is a consultant for CareDx and Natera.
Y.X. and S.S. are employees of and own stock in Fulgent Genetics.
M.W., J.X., M.S.B., K.B., S.P., Z.P.D., H.T., P.R.B., and T.M. are
employees of Natera, Inc. with the option to own stock. F.J. and
S.K. have no conflicts of interest to declare.
Funding Sources
This study received no funding.
Author Contributions
T.M. and J.X. conceived and designed the research; Y.X., S.S.,
J.J.E., M.Z.M., W.K., and P.M. performed data acquisition; M.W.
and M.S.B. analyzed the data; A.B., J.X., S.P., M.S.B., S.K., and T.M.
interpreted the results; A.B., M.W., K.B., J.X., M.S.B., Z.D., and
T.M. drafted the manuscript; H.T. and P.R.B. oversaw the study
design. All authors reviewed and approved the final version of the
manuscript.
Data Availability Statement
The data that support the findings of this study are available on
request from the corresponding author. The clinical and demographic data are not publicly available due to privacy or ethical
restrictions. All P/LP variants have been reported to and are accessible through ClinVar [35].
9
References
1 Centers for Disease Control and Prevention:
Chronic Kidney Disease in the United States,
2019 [Available from: https: //www.cdc.gov/
kidneydisease/pdf/2019_National-ChronicKidney-Disease-Fact-Sheet.pdf]
(accessed
March 31, 2021).
2 Vivante A, Skorecki K. Introducing routine
genetic testing for patients with CKD. Nat Rev
Nephrol. 2019;15(6):321–2.
3 Groopman EE, Marasa M, Cameron-Christie
S, Petrovski S, Aggarwal VS, Milo-Rasouly H,
et al. Diagnostic utility of exome sequencing
for kidney disease. N Engl J Med. 2019;380(2):
142–51.
4 Jayasinghe K, Quinlan C, Mallett AJ, Kerr PG,
McClaren B, Nisselle A, et al. Attitudes and
practices of Australian nephrologists toward
implementation of clinical genomics. Kidney
Int Rep. 2021;6(2):272–83.
5 Lata S, Marasa M, Li Y, Fasel DA, Groopman
E, Jobanputra V, et al. Whole-exome sequencing in adults with chronic kidney disease: a pilot study. Ann Intern Med. 2018;
168(2):100–9.
6 Connaughton DM, Kennedy C, Shril S, Mann
N, Murray SL, Williams PA, et al. Monogenic
causes of chronic kidney disease in adults.
Kidney Int. 2019;95(4):914–28.
7 Snoek R, van Jaarsveld RH, Nguyen TQ, Peters EDJ, Elferink MG, Ernst RF, et al. Genetics-first approach improves diagnostics of
ESKD patients younger than 50 years.
Nephrol Dial Transplant. 2022;37(2):349–57.
8 Murray SL, Dorman A, Benson KA, Connaughton DM, Stapleton CP, Fennelly NK, et
al. Utility of genomic testing after renal biopsy. Am J Nephrol. 2020;51(1):43–53.
9 Schrezenmeier E, Kremerskothen E, Halleck
F, Staeck O, Liefeldt L, Choi M, et al. The underestimated burden of monogenic kidney
disease in adults waitlisted for kidney transplantation. Genet Med. 2021;23(7):1219–24.
10 Jayasinghe K, Stark Z, Kerr PG, Gaff C, Martyn M, Whitlam J, et al. Clinical impact of genomic testing in patients with suspected
monogenic kidney disease. Genet Med. 2021;
23(1):183–91.
11 Mansilla MA, Sompallae RR, Nishimura CJ,
Kwitek AE, Kimble MJ, Freese ME, et al. Targeted broad-based genetic testing by nextgeneration sequencing informs diagnosis and
facilitates management in patients with kidney diseases. Nephrol Dial Transplant. 2021;
36(2):295–305.
12 Lee CY, Yen HY, Zhong AW, Gao H. Resolving misalignment interference for NGS-based
clinical diagnostics. Hum Genet. 2021;140(3):
477–92.
10
Am J Nephrol
DOI: 10.1159/000522226
13 Richards S, Aziz N, Bale S, Bick D, Das S,
Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of
the American College of Medical Genetics
and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5):
405–24.
14 Savige J, Storey H, Watson E, Hertz JM, Deltas
C, Renieri A, et al. Consensus statement on
standards and guidelines for the molecular diagnostics of Alport syndrome: refining the
ACMG criteria. Eur J Hum Genet. 2021;29(8):
1186–97.
15 Clinical Genome Resource: Kidney Disease
CDWG 2021 [Available from: https: //clinicalgenome.org/working-groups/clinical-domain/clingen-kidney-disease-clinical-domain-working-group/] (accessed January 20,
2021).
16 Albertus P, Morgenstern H, Robinson B, Saran R. Risk of ESRD in the United States. Am
J Kidney Dis. 2016;68(6):862–72.
17 Naik RP, Derebail VK, Grams ME, Franceschini N, Auer PL, Peloso GM, et al. Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans.
JAMA. 2014;312(20):2115–25.
18 Mallawaarachchi AC, Lundie B, Hort Y,
Schonrock N, Senum SR, Gayevskiy V, et al.
Genomic diagnostics in polycystic kidney disease: an assessment of real-world use of
whole-genome sequencing. Eur J Hum Genet.
2021;29(5):760–70.
19 Cornec-Le Gall E, Audrezet MP, Rousseau A,
Hourmant M, Renaudineau E, Charasse C, et
al. The PROPKD score: a new algorithm to
predict renal survival in autosomal dominant
polycystic kidney disease. J Am Soc Nephrol.
2016;27(3):942–51.
20 Chebib FT, Perrone RD, Chapman AB, Dahl
NK, Harris PC, Mrug M, et al. A Practical
guide for treatment of rapidly progressive
ADPKD with tolvaptan. J Am Soc Nephrol.
2018;29(10):2458–70.
21 Warady BA, Agarwal R, Bangalore S, Chapman A, Levin A, Stenvinkel P, et al. Alport
syndrome classification and management.
Kidney Med. 2020;2(5):639–49.
22 Kashtan CE, Ding J, Garosi G, Heidet L, Massella L, Nakanishi K, et al. Alport syndrome: a
unified classification of genetic disorders of
collagen IV alpha345: a position paper of the
alport syndrome classification working
group. Kidney Int. 2018;93(5):1045–51.
23 Vivante A, Chacham OS, Shril S, Schreiber R,
Mane SM, Pode-Shakked B, et al. Dominant
PAX2 mutations may cause steroid-resistant
nephrotic syndrome and FSGS in children.
Pediatr Nephrol. 2019;34(9):1607–13.
24 Bedin M, Boyer O, Servais A, Li Y, VilloingGaude L, Tete MJ, et al. Human C-terminal
CUBN variants associate with chronic proteinuria and normal renal function. J Clin Invest. 2020;130(1):335–44.
25 Foster MC, Coresh J, Fornage M, Astor BC,
Grams M, Franceschini N, et al. APOL1 variants associate with increased risk of CKD
among African Americans. J Am Soc Nephrol.
2013;24(9):1484–91.
26 Naik RP, Irvin MR, Judd S, Gutierrez OM, Zakai NA, Derebail VK, et al. Sickle Cell Trait
and the Risk of ESRD in Blacks. J Am Soc
Nephrol. 2017;28(7):2180–7.
27 United States Renal Data System. 2020
USRDS annual data report: epidemiology of
kidney disease in the United States. Bethesda,
MD, USA: National Institutes of Health, National Institute of Diabetes and Digestive and
Kidney Diseases; 2020.
28 Jacobson DR, Pastore RD, Yaghoubian R,
Kane I, Gallo G, Buck FS, et al. Variant-sequence transthyretin (isoleucine 122) in lateonset cardiac amyloidosis in black Americans. N Engl J Med. 1997;336(7):466–73.
29 Lobato L, Rocha A. Transthyretin amyloidosis and the kidney. Clin J Am Soc Nephrol.
2012;7(8):1337–46.
30 Olaniran KO, Allegretti AS, Zhao SH, Achebe
MM, Eneanya ND, Thadhani RI, et al. Kidney
function decline among black patients with
sickle cell trait and sickle cell disease: an observational cohort study. J Am Soc Nephrol.
2020;31(2):393–404.
31 Centers for Disease Control and Prevention:
Data & Statistics on Sickle Cell Disease 2020
https: //www.cdc.gov/
[Available from:
ncbddd/sicklecell/data.html] (accessed April
20, 2021).
32 Bleyer AJ, Kidd K, Robins V, Martin L, Taylor
A, Santi A, et al. Outcomes of patient self-referral for the diagnosis of several rare inherited kidney diseases. Genet Med. 2020; 22(1):
142–9.
33 Devuyst O, Olinger E, Weber S, Eckardt KU,
Kmoch S, Rampoldi L, et al. Autosomal dominant tubulointerstitial kidney disease. Nat
Rev Dis Primers. 2019;5(1):60.
34 Mrug M, Bloom MS, Seto C, Malhotra M, Tabriziani H, Gauthier P, et al. Genetic testing
for chronic kidney diseases: clinical utility
and barriers perceived by nephrologists. Kidney Med. 2021;3(6):1050–6.
35 Landrum MJ, Lee JM, Benson M, Brown GR,
Chao C, Chitipiralla S, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;
46(D1):D1062–7.
Bleyer et al.